SM
RCKT icon

Sabby Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Sabby Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-53,163
Closed -$404K – 201
2017
Q2 		$404K Buy
53,163
+27,930
+111% +$208K 0.03% 153
2017
Q1 		$202K Sell
25,233
-12,500
-33% -$84.1K 0.01% 216
2016
Q4 		$921K Buy
37,733
+1,732
+5% +$49.4K 0.05% 151
2016
Q3 		$1.36M Buy
36,001
+9,387
+35% +$295K 0.05% 158
2016
Q2 		$792K Sell
26,614
-2,500
-9% -$87.9K 0.04% 180
2016
Q1 		$862K Buy
29,114
+7,201
+33% +$216K 0.04% 165
2015
Q4 		$993K Sell
21,913
-5,587
-20% -$243K 0.05% 185
2015
Q3 		$1.03M Buy
+27,500
New +$1.26M 0.04% 231

Other funds holding RCKT

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sabby Management's RCKT Position: Q3 2017 in Review

Sabby Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 53,163 shares — an estimated $404K sold.

Sabby Management first reported a position in RCKT in Q3 2015 and held it in 8 quarters. The position peaked at $1.36M in Q3 2016. 35 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

  • Sabby Management reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 53,163 Rocket Pharmaceuticals shares in Q3 2017, an estimated $404K.
  • Sabby Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 8 quarters.
  • Sabby Management's Rocket Pharmaceuticals position peaked at $1.36M in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.